Related references
Note: Only part of the references are listed.Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis
Hadi Mostafaei et al.
EUROPEAN UROLOGY FOCUS (2022)
The effects of oral administration of the novel muscarinic receptor antagonist DA-8010 on overactive bladder in rat with bladder outlet obstruction
Jin Bong Choi et al.
BMC UROLOGY (2020)
Pharmacological characterization of DA-8010, a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland
Min Jung Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice
Christopher R. Chapple et al.
EUROPEAN UROLOGY (2017)
Detection of muscarinic receptor subtypes in human urinary bladder mucosa: Age and gender-dependent modifications
Nicola Arrighi et al.
NEUROUROLOGY AND URODYNAMICS (2008)
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder
Paul Abrams et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder
F Haab et al.
EUROPEAN UROLOGY (2004)
M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland
K Ikeda et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2002)
Which muscarinic receptor is important in the bladder?
T Yamanishi et al.
WORLD JOURNAL OF UROLOGY (2001)
Share Paper
